Eisai Primes Push For Biogen MS Range In India

 
• By Anju Ghangurde

Eisai is straddling a mix of new opportunities for growth in India as it takes charge of sales of Biogen’s multiple sclerosis portfolio in the country and also eyes potential gains from its Japanese parent’s recent deal with Nichi-Iko.

Jigsaw
EISAI IS USING A MULTI-PRONGED APPROACH TO EXPAND THE MS MARKET IN INDIA

More from Business

More from Scrip